We are analyzing https://link.springer.com/article/10.1007/s00262-015-1782-5.

Title:
Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study | Cancer Immunology, Immunotherapy
Description:
There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their phenotypic definition. To overcome this obstacle, the Cancer Immunoguiding Program under the umbrella of the Association of Cancer Immunotherapy is coordinating a proficiency panel program that aims at harmonizing MDSC phenotyping. After a consultation period, a two-stage approach was designed to harmonize MDSC phenotype. In the first step, an international consortium of 23 laboratories immunophenotyped 10 putative MDSC subsets on pretested, peripheral blood mononuclear cells of healthy donors to assess the level of concordance and define robust marker combinations for the identification of circulating MDSCs. At this stage, no mandatory requirements to standardize reagents or protocols were introduced. Data analysis revealed a small intra-laboratory, but very high inter-laboratory variance for all MDSC subsets, especially for the granulocytic subsets. In particular, the use of a dead-cell marker altered significantly the reported percentage of granulocytic MDSCs, confirming that these cells are especially sensitive to cryopreservation and/or thawing. Importantly, the gating strategy was heterogeneous and associated with high inter-center variance. Overall, our results document the high variability in MDSC phenotyping in the multicenter setting if no harmonization/standardization measures are applied. Although the observed variability depended on a number of identified parameters, the main parameter associated with variation was the gating strategy. Based on these findings, we propose further efforts to harmonize marker combinations and gating parameters to identify strategies for a robust enumeration of MDSC subsets.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

mdsc, cells, cancer, subsets, pubmed, article, panel, mdscs, gating, google, scholar, cas, variance, cell, suppressor, results, laboratories, data, human, university, myeloidderived, proficiency, participants, patients, fig, immunol, strategy, myeloid, color, central, analysis, phenotyping, cytometry, number, flow, mandruzzato, identification, germany, marker, high, granulocytic, identified, markers, staining, panels, usa, britten, interlaboratory, immature, lymphocytes,

Topics {✒️}

mdsc7 cd15−/cd14+/cd33high/hla-drlow [18] mdsc7 cd15−/cd14+/cd33high/hla-drlow/− [18] myeloid-derived suppressor cells mdsc10 lin−/hla-drlow/cd11b+ [19] mdsc10 lin−/hla-drlow/−/cd11b+ [19] granulocyte-derived hydrogen peroxide cd11b+/gr-1high/ly6c−/ly6ghigh cd11b+/gr-1int/ly6chigh/ly6g− [6] mdsc3 lin−/hla-dr−/cd33+ [10] mdsc3 lin−/hla-dr−/cd33+ [10 article download pdf myeloid suppressor cells mdsc4 cd14+/hla-drlow/− [11] hla-peptide multimer assay mdsc6 cd15+/fsclow/sschigh [13] wilcoxon signed-rank test wilcoxon matched-pair test myeloid cell-mediated immunosuppression mdsc9 cd14−/cd15−/cd33high immatics biotechnologies gmbh van der burg & marij single-dose cyclophosphamide associates high inter-laboratory variance reports inter-laboratory variance multimer-based proficiency panel high inter-center variance high inter-laboratory variation inter-laboratory variability arises calculate intra-laboratory variance mdsc5 cd15+/cd14−/cd11b+ [15] diaz-montero cm immature myeloid cells van der burg cd33 positive cells colony-stimulating factors renal cell carcinoma privacy choices/manage cookies immune suppression mediated highly fluorescent cells dimly fluorescent cells cd11b+/gr-1+ cells hla-multimer staining phenotypic definition mdsc8 cd15+/cd33high cancer vaccine ima901 inter-laboratory variance data analysis revealed dead-cell marker multipeptide immune response proficiency panels based

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
         description:There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their phenotypic definition. To overcome this obstacle, the Cancer Immunoguiding Program under the umbrella of the Association of Cancer Immunotherapy is coordinating a proficiency panel program that aims at harmonizing MDSC phenotyping. After a consultation period, a two-stage approach was designed to harmonize MDSC phenotype. In the first step, an international consortium of 23 laboratories immunophenotyped 10 putative MDSC subsets on pretested, peripheral blood mononuclear cells of healthy donors to assess the level of concordance and define robust marker combinations for the identification of circulating MDSCs. At this stage, no mandatory requirements to standardize reagents or protocols were introduced. Data analysis revealed a small intra-laboratory, but very high inter-laboratory variance for all MDSC subsets, especially for the granulocytic subsets. In particular, the use of a dead-cell marker altered significantly the reported percentage of granulocytic MDSCs, confirming that these cells are especially sensitive to cryopreservation and/or thawing. Importantly, the gating strategy was heterogeneous and associated with high inter-center variance. Overall, our results document the high variability in MDSC phenotyping in the multicenter setting if no harmonization/standardization measures are applied. Although the observed variability depended on a number of identified parameters, the main parameter associated with variation was the gating strategy. Based on these findings, we propose further efforts to harmonize marker combinations and gating parameters to identify strategies for a robust enumeration of MDSC subsets.
         datePublished:2016-01-04T00:00:00Z
         dateModified:2016-01-04T00:00:00Z
         pageStart:161
         pageEnd:169
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00262-015-1782-5
         keywords:
            Myeloid-derived suppressor cells
            Phenotyping
            Proficiency panel
            Flow cytometry
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:65
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Susanna Mandruzzato
               url:http://orcid.org/0000-0002-0707-995X
               affiliation:
                     name:University of Padova
                     address:
                        name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
                     name:Veneto Institute of Oncology IOV - IRCCS
                     address:
                        name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sven Brandau
               affiliation:
                     name:University Hospital Essen
                     address:
                        name:Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cedrik M. Britten
               affiliation:
                     name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH
                     address:
                        name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH, Mainz, Germany
                        type:PostalAddress
                     type:Organization
                     name:GlaxoSmithKline
                     address:
                        name:Cell Therapy Group, Immuno-Oncology and Combinations, GlaxoSmithKline, Stevenage, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vincenzo Bronte
               affiliation:
                     name:Verona University Hospital
                     address:
                        name:Section of Immunology, Department of Pathology and Diagnostics, Verona University Hospital, Verona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vera Damuzzo
               affiliation:
                     name:University of Padova
                     address:
                        name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
                     name:Veneto Institute of Oncology IOV - IRCCS
                     address:
                        name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cécile Gouttefangeas
               affiliation:
                     name:University of Tübingen
                     address:
                        name:Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dominik Maurer
               affiliation:
                     name:Immatics Biotechnologies GmbH
                     address:
                        name:Immatics Biotechnologies GmbH, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christian Ottensmeier
               affiliation:
                     name:University of Southampton
                     address:
                        name:Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital, University of Southampton, Southampton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sjoerd H. van der Burg
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marij J. P. Welters
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steffen Walter
               affiliation:
                     name:Immatics Biotechnologies GmbH
                     address:
                        name:Immatics Biotechnologies GmbH, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
      description:There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their phenotypic definition. To overcome this obstacle, the Cancer Immunoguiding Program under the umbrella of the Association of Cancer Immunotherapy is coordinating a proficiency panel program that aims at harmonizing MDSC phenotyping. After a consultation period, a two-stage approach was designed to harmonize MDSC phenotype. In the first step, an international consortium of 23 laboratories immunophenotyped 10 putative MDSC subsets on pretested, peripheral blood mononuclear cells of healthy donors to assess the level of concordance and define robust marker combinations for the identification of circulating MDSCs. At this stage, no mandatory requirements to standardize reagents or protocols were introduced. Data analysis revealed a small intra-laboratory, but very high inter-laboratory variance for all MDSC subsets, especially for the granulocytic subsets. In particular, the use of a dead-cell marker altered significantly the reported percentage of granulocytic MDSCs, confirming that these cells are especially sensitive to cryopreservation and/or thawing. Importantly, the gating strategy was heterogeneous and associated with high inter-center variance. Overall, our results document the high variability in MDSC phenotyping in the multicenter setting if no harmonization/standardization measures are applied. Although the observed variability depended on a number of identified parameters, the main parameter associated with variation was the gating strategy. Based on these findings, we propose further efforts to harmonize marker combinations and gating parameters to identify strategies for a robust enumeration of MDSC subsets.
      datePublished:2016-01-04T00:00:00Z
      dateModified:2016-01-04T00:00:00Z
      pageStart:161
      pageEnd:169
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00262-015-1782-5
      keywords:
         Myeloid-derived suppressor cells
         Phenotyping
         Proficiency panel
         Flow cytometry
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-015-1782-5/MediaObjects/262_2015_1782_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:65
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Susanna Mandruzzato
            url:http://orcid.org/0000-0002-0707-995X
            affiliation:
                  name:University of Padova
                  address:
                     name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
                  name:Veneto Institute of Oncology IOV - IRCCS
                  address:
                     name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sven Brandau
            affiliation:
                  name:University Hospital Essen
                  address:
                     name:Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cedrik M. Britten
            affiliation:
                  name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH
                  address:
                     name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH, Mainz, Germany
                     type:PostalAddress
                  type:Organization
                  name:GlaxoSmithKline
                  address:
                     name:Cell Therapy Group, Immuno-Oncology and Combinations, GlaxoSmithKline, Stevenage, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vincenzo Bronte
            affiliation:
                  name:Verona University Hospital
                  address:
                     name:Section of Immunology, Department of Pathology and Diagnostics, Verona University Hospital, Verona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vera Damuzzo
            affiliation:
                  name:University of Padova
                  address:
                     name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
                  name:Veneto Institute of Oncology IOV - IRCCS
                  address:
                     name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cécile Gouttefangeas
            affiliation:
                  name:University of Tübingen
                  address:
                     name:Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dominik Maurer
            affiliation:
                  name:Immatics Biotechnologies GmbH
                  address:
                     name:Immatics Biotechnologies GmbH, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christian Ottensmeier
            affiliation:
                  name:University of Southampton
                  address:
                     name:Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital, University of Southampton, Southampton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sjoerd H. van der Burg
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marij J. P. Welters
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steffen Walter
            affiliation:
                  name:Immatics Biotechnologies GmbH
                  address:
                     name:Immatics Biotechnologies GmbH, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:65
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Padova
      address:
         name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
         type:PostalAddress
      name:Veneto Institute of Oncology IOV - IRCCS
      address:
         name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
         type:PostalAddress
      name:University Hospital Essen
      address:
         name:Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
         type:PostalAddress
      name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH
      address:
         name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH, Mainz, Germany
         type:PostalAddress
      name:GlaxoSmithKline
      address:
         name:Cell Therapy Group, Immuno-Oncology and Combinations, GlaxoSmithKline, Stevenage, UK
         type:PostalAddress
      name:Verona University Hospital
      address:
         name:Section of Immunology, Department of Pathology and Diagnostics, Verona University Hospital, Verona, Italy
         type:PostalAddress
      name:University of Padova
      address:
         name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
         type:PostalAddress
      name:Veneto Institute of Oncology IOV - IRCCS
      address:
         name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
         type:PostalAddress
      name:University of Tübingen
      address:
         name:Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Immatics Biotechnologies GmbH
      address:
         name:Immatics Biotechnologies GmbH, Tübingen, Germany
         type:PostalAddress
      name:University of Southampton
      address:
         name:Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital, University of Southampton, Southampton, UK
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Immatics Biotechnologies GmbH
      address:
         name:Immatics Biotechnologies GmbH, Tübingen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Susanna Mandruzzato
      url:http://orcid.org/0000-0002-0707-995X
      affiliation:
            name:University of Padova
            address:
               name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
            name:Veneto Institute of Oncology IOV - IRCCS
            address:
               name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sven Brandau
      affiliation:
            name:University Hospital Essen
            address:
               name:Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Cedrik M. Britten
      affiliation:
            name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH
            address:
               name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH, Mainz, Germany
               type:PostalAddress
            type:Organization
            name:GlaxoSmithKline
            address:
               name:Cell Therapy Group, Immuno-Oncology and Combinations, GlaxoSmithKline, Stevenage, UK
               type:PostalAddress
            type:Organization
      name:Vincenzo Bronte
      affiliation:
            name:Verona University Hospital
            address:
               name:Section of Immunology, Department of Pathology and Diagnostics, Verona University Hospital, Verona, Italy
               type:PostalAddress
            type:Organization
      name:Vera Damuzzo
      affiliation:
            name:University of Padova
            address:
               name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
            name:Veneto Institute of Oncology IOV - IRCCS
            address:
               name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Cécile Gouttefangeas
      affiliation:
            name:University of Tübingen
            address:
               name:Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Dominik Maurer
      affiliation:
            name:Immatics Biotechnologies GmbH
            address:
               name:Immatics Biotechnologies GmbH, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Christian Ottensmeier
      affiliation:
            name:University of Southampton
            address:
               name:Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital, University of Southampton, Southampton, UK
               type:PostalAddress
            type:Organization
      name:Sjoerd H. van der Burg
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Marij J. P. Welters
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Steffen Walter
      affiliation:
            name:Immatics Biotechnologies GmbH
            address:
               name:Immatics Biotechnologies GmbH, Tübingen, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
      name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
      name:Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
      name:TRON Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GmbH, Mainz, Germany
      name:Cell Therapy Group, Immuno-Oncology and Combinations, GlaxoSmithKline, Stevenage, UK
      name:Section of Immunology, Department of Pathology and Diagnostics, Verona University Hospital, Verona, Italy
      name:Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
      name:Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
      name:Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany
      name:Immatics Biotechnologies GmbH, Tübingen, Germany
      name:Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital, University of Southampton, Southampton, UK
      name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
      name:Immatics Biotechnologies GmbH, Tübingen, Germany

External Links {🔗}(162)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.25s.

LINK . SPRINGER . COM {}